The Demise of the Blockbuster?

Publisher Website
Google Scholar
Abstract
When Pfizer announced that it was halting clinical testing of its new cholesterol drug, torcetrapib, the company's market value fell by $21 billion overnight. Ten thousand job cuts followed. The ongoing promise of nearly $3 billion in annual sales vanished when Merck pulled Vioxx (rofecoxib) from the shelves, and the company's market value fell by $25 billion. For decades, blockbuster drugs have nourished Big Pharma, but it is increasingly uncertain whether they can be counted on to support the industry in the future.Prescription medications are extremely costly to develop and market. The cost of bringing a new drug to . . .

This publication has 3 references indexed in Scilit: